OCTA Biomarker Search in Patients with nAMD: Influence of Retinal Fluid on Time-Dependent Biomarker Response

Abstract Purpose Previous studies have identified a link between optical coherence tomography (OCT)-derived and OCT angiography (OCTA)-based parameters in patients with neovascular AMD (nAMD); the latter may serve as direct biomarkers for macular neovascularization (MNV) activity. The aim of this study was to assess the individual influence of retinal thickness (RT) as well as intra- and sub-retinal fluid (IRF, SRF) presence on the treatment response over time as assessed by previously identified OCTA-derived MNV vascular parameters. Methods During the first 3 months of anti-VEGF therapy patients were prospectively followed. RT, SRF and IRF were determined from SSOCT/A (PlexElite, Zeiss) images and using the semi-automated AngioTool software, vessel area (VA), total vessel length (TVL), total number of junctions (TNJ), junction density (JD), vessel density (VD) as well as MNV area were exported. IRF and SRF were identified manually on OCT volume scans .The associations between RT, IRF, and SRF and SSOCTA vascular parameters were analyzed using linear mixed models. Results 31 eyes of 31 patients with treatment-naïve and OCTA-positive nAMD MNV were included in this analysis. VA, TVL, TNJ, and MNV area show a statistically significant change over time in response to anti-VEGF treatment, even after correcting for the presence of SRF, IRF, or RT (all p < 0.05). This is not the case for JD and VD (both p > 0.05). Conclusions OCTA-based parameters VA, TVL, TNJ, and MNVarea show a strong response to anti-VEGF therapy over time, independent of the presence of IRF, SRF or RT. We conclude that the above listed OCTA parameters could contribute to our understanding of MNV biology and to guide individualized treatment in the future. Trial registry The authors confirm that all ongoing and related trials are registered. ClinicalTrials.gov Number: NCT02521142

[1]  M. Rispoli,et al.  Biomarkers in Early Response to Brolucizumab on Pigment Epithelium Detachment Associated with Exudative Age-Related Macular Degeneration , 2021, Biomedicines.

[2]  U. Schmidt-Erfurth,et al.  Impact of Residual Subretinal Fluid Volumes on Treatment Outcomes in a SRF-tolerant Treat & Extend Regimen. , 2021, Retina.

[3]  Qinghua Qiu,et al.  Imaging Hyperreflective Foci as an Inflammatory Biomarker after Anti-VEGF Treatment in Neovascular Age-Related Macular Degeneration Patients with Optical Coherence Tomography Angiography , 2021, BioMed research international.

[4]  U. Schmidt-Erfurth,et al.  Correlation of Retinal Thickness and Swept-Source Optical Coherence Tomography Angiography Derived Vascular Changes in Patients with Neovascular Age-Related Macular Degeneration , 2020, Current eye research.

[5]  U. Schmidt-Erfurth,et al.  Profiling neovascular age‐related macular degeneration choroidal neovascularization lesion response to anti‐vascular endothelial growth factor therapy using SSOCTA , 2020, Acta ophthalmologica.

[6]  M. Puyraveau,et al.  Predictive factors for exudation of quiescent choroidal neovessels detected by OCT angiography in the fellow eyes of eyes treated for a neovascular age-related macular degeneration , 2020, Eye.

[7]  Yong Kyun Shin,et al.  Predictors of neovascular activity during neovascular age-related macular degeneration treatment based on optical coherence tomography angiography , 2019, Scientific Reports.

[8]  F. Holz,et al.  Assessment of Exudative Activity of Choroidal Neovascularization in Age-Related Macular Degeneration by OCT Angiography , 2019, Ophthalmologica.

[9]  O. Polat,et al.  The association of exudation pattern with anatomical and functional outcomes in patients with Neovascular Age-Related Macular Degeneration , 2019, Romanian journal of ophthalmology.

[10]  Amani A Fawzi,et al.  Projection resolved optical coherence tomography angiography to distinguish flow signal in retinal angiomatous proliferation from flow artifact , 2019, PloS one.

[11]  R. Guymer,et al.  Tolerating Subretinal Fluid in Neovascular Age-Related Macular Degeneration Treated with Ranibizumab Using a Treat-and-Extend Regimen: FLUID Study 24-Month Results. , 2019, Ophthalmology.

[12]  H. Faatz,et al.  Optical coherence tomography angiography of types 1 and 2 choroidal neovascularization in age-related macular degeneration during anti-VEGF therapy: evaluation of a new quantitative method , 2019, Eye.

[13]  M. Varano,et al.  A Comparison Among Different Automatically Segmented Slabs to Assess Neovascular AMD using Swept Source OCT Angiography , 2019, Translational vision science & technology.

[14]  H. Terasaki,et al.  Optical Coherence Tomography Angiography to Quantify Choroidal Neovascularization in Response to Aflibercept , 2018, Ophthalmologica.

[15]  R. Spaide Optical Coherence Tomography Angiography Signs of Vascular Abnormalization With Antiangiogenic Therapy for Choroidal Neovascularization. , 2015, American journal of ophthalmology.

[16]  Laure Gambardella,et al.  A Computational Tool for Quantitative Analysis of Vascular Networks , 2011, PloS one.

[17]  Bianca S. Gerendas,et al.  Machine Learning to Analyze the Prognostic Value of Current Imaging Biomarkers in Neovascular Age-Related Macular Degeneration. , 2018, Ophthalmology. Retina.